Key Summary: On October 29, 2024, Nant Capital (33.3%) engaged with management, the board, and significant shareholders about strategies to maximize shareholder value.
Market Cap: $1.5 million | Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
On October 29, 2024, Nant Capital (33.3%) has been and may continue to be in contact with members of the management, the board, other significant shareholders and others regarding alternatives that the company could employ to maximize shareholder value. Source
Comments